• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Show Search
Home
EN / FR
  • LinkedIn
  • Twitter
  • YouTube
Celyad Oncology

Celyad Oncology

  • About Us
    • Overview
    • Management Team
    • Board Of Directors
    • Scientific Advisory Board
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • TIM
      • shRNA
    • Manufacturing
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Contact Us
    • Careers

Home V2

ABOUT CELYAD ONCOLOGY

Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer

More Info About Celyad ONCOLOGY

Latest News

376_981be_rev 1

Shareholders Approve Rebranding as Celyad

June 9, 2020
READ THE PRESS RELEASE

Celyad Provides Update on Allogeneic CAR-T Franchise including CYAD-101 and shRNA Platform at the 2020 ASCO Virtual Scientific Program

June 1, 2020
READ THE PRESS RELEASE

Celyad Announces June 2020 Conference Schedule

May 26, 2020
READ THE PRESS RELEASE

Celyad Announces First Quarter 2020 Financial Results and Recent Business Highlights

May 7, 2020
READ THE PRESS RELEASE

Celyad Appoints Seasoned Industry Executives to Board of Directors

May 6, 2020
READ THE PRESS RELEASE

Celyad to Present Update from CYAD-101 for Advanced Colorectal Cancer and Next-Generation shRNA Platform at 2020 ASCO Virtual Scientific Program

April 30, 2020
READ THE PRESS RELEASE

Celyad to Host Remote 2020 Ordinary General Meeting

April 22, 2020
READ THE PRESS RELEASE

Celyad Reports Full Year 2019 Financial Results and Provides Business Update

March 24, 2020
READ THE PRESS RELEASE

Celyad to Announce Full Year 2019 Financial Results and Host Conference Call

March 12, 2020
READ THE PRESS RELEASE

Celyad Appoints Stephen Rubino as Chief Business Officer

March 2, 2020
READ THE PRESS RELEASE
Discover All News

Our SCIENCE

At Celyad Oncology, we are pursuing next-generation cellular immunotherapies by applying our broad understanding of immunology, novel technology platforms and modular design approach to drug discovery.

Read More About Our SCIENCE

Novel CAR T Immunotherapies

Advancing both allogeneic and autologous CAR T therapy candidates for the treatment of cancer

View Pipeline
Getty_488635681_lowres 1

Celyad Oncology@CelyadSA·
19 May

#TBT - A few months ago, we presented updates on our shRNA-based #CAR_T Programs. While we prepare to announce our CYAD-211 data in the second half of the year, catch up on our most recent news here: https://buff.ly/3yFaq04

Celyad Oncology@CelyadSA·
18 May

#DYK there many types of cancer treatment? Treatments including cell therapy, chemo, surgery, and immunotherapy could be a solution to this disease. Learn more about the cancer treatment types by clicking here: https://buff.ly/2JzrA2B

View All

Stay informed about the latest news!

Sign up FOR our newsletter

Please enter a valid email address.
Submit

Thanks for subscribing! Please check your email for further instructions.

Something went wrong. Please check your entries and try again.

By clicking on “send”, you accept that your data will be sent to us and processed by our provider in order to send you our newsletter. You can find more information on how we process your data in our Privacy Policy.

Footer

  • About
  • Science
  • Pipeline
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter
  • YouTube

Copyright © 2020 All Rights Reserved.
Cookie Policy | Privacy Policy | Terms of Use

Our website uses cookies including analytics cookies to help us improve it by collecting statistics on how visitors use our website. By clicking on “I accept”, you allow us to place these analytics cookies. We also use cookies that are necessary for the good-functioning of our website. You can find more information about the cookies we use by visiting our Cookie Policy.I AcceptI RefuseCookie Policy